We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance on using non-investigational medicinal products in a clinical trial.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Product defect recall alert for Folltropin 700 IU Powder and Solvent for Solution for Injection by Vetoquinol SA and Vetoquinol UK Limited.
Guidance on transitional arrangements for the Clinical Trials Regulations.
How to apply for a clinical trial from 28 April 2026, including eligibility, documentation and registration in a public registry.
Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm.
This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).